Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Thymoma 1Squamous Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1NSCLC 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 24Nivolumab 19atezolizumab 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7durvalumab 5Ipilimumab 5fludarabine 4Trastuzumab 4cemiplimab 3cabozantinib 3avelumab 3Sunitinib 3Biopsy 3ulixertinib 2toripalimab 2tislelizumab 2spartalizumab 2sargramostim 2relatlimab 2palbociclib 2lenvatinib 2epacadostat 2enzalutamide 2cyclopropapyrroloindole 2copanlisib 2budigalimab 2aldesleukin 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × envafolimab × Thoracic × Clear all
NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡